Biohaven Pharma (NYSE: BHVN) reported Q2 EPS of ($3.23), $0.49 worse than the analyst estimate of ($2.74). Revenue for the quarter came in at $92.93 million versus the consensus estimate of $78.13 million.

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.